Servizio Comunitario di Informazione in materia di Ricerca e Sviluppo - CORDIS

FP6

BIOTPHEX Sintesi della relazione

Project ID: 508054
Finanziato nell'ambito di: FP6-SME
Paese: Finland

Final Report Summary - BIOTPHEX (Multiplex bioassays using the two-photon excitation method)

The main objective of the 'Multiplex bioassays using the two-photon excitation method' (BIOTPHEX) project was development of applications ad technology and components for Arcdia's and Luxcel's diagnostics and biotechnology products. Other small and medium-sized enterprise (SME) partners had the role of developing special components for the related applications.

Besides many results of BIOTPHEX project that may have commercial potential, two major business opportunities have been identified in the field of biotechnology and diagnostics. Related business plans have been made or are under preparation:
- distributed in vitro diagnostics concept (Arctic diagnostics Oy - Arcdia Ltd, Finland);
- a new concept for rapid assay of infection diseases (Arcdia);
- a new methodology for methicillin-resistant Staphylococcus aureus (MRSA) detection (Arcdia);
- research and development (R&D) tools and solutions to the research community (Luxcel Biosciences Ltd, Ireland).

In addition other SME partners have developed new components, which outside bioscience applications may have potential in the optical component market:
- microchip lasers (Standa optomechanical producers;
- certain fibre lasers (New optics/Fianium Ltd, UK);
- microfluidics chips (Merlin technologies GmbH, Germany).

BIOTPHEX project has resulted in a new concept for rapid assay methods for most common pathogens causing respiratory infection. These pathogens include streptococcus A, streptococcus B, influenza A, influenza B, adenovirus, and respiratory syncytial virus (RSV). These six pathogens are responsible in 90 % of respiratory infection cases. A multianalyte diagnostic product for rapid point-of-care testing of these pathogens would be valuable tool in the primary health care. The use of such diagnostic product would thus allow pathogen specific medication, and would lead to elimination of unnecessary antibiotics prescription.

Based on the results of this project, the researchers of UTU and Arcdia consider that the detection of pathogens causing respiratory infections is one the most potential application area for TPX detection technique. Rapid multianalyte testing of such pathogens in the doctor's office would allow differentiation between viral and bacterial infection, and prescription of specific medication against the identified pathogen.

According to the current practice, a cotton swab sample is taken from the patient for microbiological analysis, or alternatively, the patient is prescribed directly with wide spectrum antibiotics. Microbiological analyses are expensive and time consuming providing results no faster than 24 hours, while direct prescription of wide spectrum antibiotics is harmful for the normal flora of the patient, and tends to lead formation of new resistant bacterial strains.

BIOTPHEX project has resulted in a new rapid methodology for bacterial antibiotic sensitivity testing allows for the first time antibiotic sensitivity testing of MRSA samples during a few hours time. The methodology eliminates the need of pre-culturing (takes normally two days) the patient samples.
The rapid methodology for bacterial antibiotic sensitivity determination has been verified with staphylococcus aureus and streptococcus pyogenes by various samples with high non-specific bacterial contamination.

Informazioni correlate

Contatto